Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,040 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.
Le Cesne A, Chevreau C, Perrin C, Italiano A, Hervieu A, Blay JY, Piperno-Neumann S, Saada-Bouzid E, Bertucci F, Firmin N, Kalbacher E, Narciso B, Schiffler C, Yara S, Jimenez M, Bouvier C, Vidal V, Chabaud S, Duffaud F. Le Cesne A, et al. Among authors: blay jy. ESMO Open. 2023 Jun;8(3):101569. doi: 10.1016/j.esmoop.2023.101569. Epub 2023 Jun 6. ESMO Open. 2023. PMID: 37285716 Free PMC article. Clinical Trial.
Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors.
Heudel PE, de Montfort A, Debieuvre D, Chouaid C, Carton M, Audigier-Valette C, Filleron T, Chabaud S, Stancu A, Quantin X, Hiret S, Bosquet L, Blay JY. Heudel PE, et al. Among authors: blay jy. Lung Cancer. 2023 Aug;182:107280. doi: 10.1016/j.lungcan.2023.107280. Epub 2023 Jun 16. Lung Cancer. 2023. PMID: 37339550
[Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups].
Collineau B, Genestie C, Croce S, Meeus P, Floquet A, Guyon F, Llacer-Moscardo C, Lebreton C, Taieb S, Toulmonde M, Blay JY, Bonvalot S, Ray-Coquard I, Pautier P, Duffaud F. Collineau B, et al. Among authors: blay jy. Bull Cancer. 2023 Apr;110(4):440-449. doi: 10.1016/j.bulcan.2023.01.009. Epub 2023 Feb 28. Bull Cancer. 2023. PMID: 36863922 Review. French.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, Italiano A, Lavernia J, Vallejo A, Tos PD, Le Loarer F, Gonzalez-Campora R, Ramos R, Hernández-Jover D, Gutierrez A, Serrano C, Monteagudo M, Letón R, Robledo M, Moura DS, Martin-Ruiz M, López-Guerrero JA, Cruz J, Fernandez-Serra A, Blay JY, Fumagalli E, Martinez-Marin V. Martin-Broto J, et al. Among authors: blay jy. Mol Cancer. 2023 Aug 9;22(1):127. doi: 10.1186/s12943-023-01832-9. Mol Cancer. 2023. PMID: 37559050 Free PMC article. Clinical Trial.
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Gelderblom H, et al. Among authors: blay jy. Eur J Cancer. 2023 Oct;192:113245. doi: 10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. Eur J Cancer. 2023. PMID: 37598656 Free article. Clinical Trial.
Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.
Deligne C, Tourbez A, Bénard F, Meyer S, Curt A, Gianesello M, Hamadou M, Clavier L, Coquet C, Bocquet C, Tomine J, Diot T, Paraqindes H, Marcel V, Berthelot C, Engel J, Rochet I, Barritault M, Savary C, Gadot N, Attignon V, Carrere M, Billaud M, Dutour A, Cordier-Bussat M, Beuriat PA, Szathmari A, Di Rocco F, Blay JY, Tiberi L, Vasiljevic A, Meyronet D, Castets M, Leblond P, Broutier L. Deligne C, et al. Among authors: blay jy. Neuro Oncol. 2025 Jan 10:noaf007. doi: 10.1093/neuonc/noaf007. Online ahead of print. Neuro Oncol. 2025. PMID: 39792378
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.
Blay JY, Brahmi M, Dufresne A, Swalduz A, Avrillon V, Assaad S, Decroisette C, Mastroianni B, Dupont M, Bourbotte-Salmon F, Ray-Coquard I, Meeus P, Dutour A, Castets M, Perol M, Heudel P. Blay JY, et al. ESMO Open. 2025 Jan 3;10(1):104088. doi: 10.1016/j.esmoop.2024.104088. Online ahead of print. ESMO Open. 2025. PMID: 39754984 Free article.
1,040 results